BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11412072)

  • 1. Rituximab for bone lymphoma.
    Savage DG; Staron R
    Ann Intern Med; 2001 Jun; 134(12):1156-7. PubMed ID: 11412072
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab for BCL-2-positive cancers.
    Boughton B
    Lancet Oncol; 2003 Feb; 4(2):69. PubMed ID: 12573343
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab for early-stage diffuse large-B-cell lymphoma.
    Friedberg JW
    Lancet Oncol; 2006 May; 7(5):357-9. PubMed ID: 16648037
    [No Abstract]   [Full Text] [Related]  

  • 4. Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma.
    Shinohara A; Asai T; Izutsu K; Ota Y; Takeuchi K; Hangaishi A; Kanda Y; Chiba S; Motokura T; Kurokawa M
    Leuk Lymphoma; 2007 Feb; 48(2):418-20. PubMed ID: 17325908
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab in diffuse large B-cell lymphoma.
    Coiffier B
    Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
    [No Abstract]   [Full Text] [Related]  

  • 6. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab.
    Yamagata M; Murohisa T; Tsuchida K; Okamoto Y; Tsunoda S; Nakamura M; Kusano K; Majima Y; Kuniyoshi T; Iijima M; Sugaya H; Hiraishi H
    Leuk Lymphoma; 2007 Feb; 48(2):431-3. PubMed ID: 17325912
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome.
    Sano T; Sakai H; Takimoto K; Ohno H
    Int J Clin Oncol; 2007 Feb; 12(1):59-62. PubMed ID: 17380444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
    Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
    Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.
    Girard T; Nochy D; Montravers F; Der Sahakian G; Fior R; Galanaud P; Boué F
    Leuk Lymphoma; 2004 Aug; 45(8):1703-5. PubMed ID: 15370230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).
    Yokose N; Shioi Y; Sugisaki Y; Ohaki Y; Ogata K; Dan K
    Leuk Lymphoma; 2006 Jul; 47(7):1415-7. PubMed ID: 16923582
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytomegalovirus enterocolitis in a patient with diffuse large B-cell lymphoma after chemotherapy with rituximab.
    Seewoodhary J
    World J Gastroenterol; 2006 Dec; 12(45):7391. PubMed ID: 17143963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature.
    Mian M; Rass C; Hutarew G; Kofler B; Fiegl M; Greil R
    Leuk Lymphoma; 2006 Aug; 47(8):1683-5. PubMed ID: 16966286
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
    Aboulafia DM
    Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?
    Crump M
    Leuk Lymphoma; 2006 Dec; 47(12):2437-9. PubMed ID: 17169786
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.
    Cook RC; Connors JM; Gascoyne RD; Fradet G; Levy RD
    Lancet; 1999 Nov; 354(9191):1698-9. PubMed ID: 10568575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab maintenance therapy in central nervous system lymphoma?
    Murawski N; Pfreundschuh M
    Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC; Zhang LZ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract]   [Full Text] [Related]  

  • 18. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.
    Dillman RO
    J Clin Oncol; 2002 Aug; 20(16):3545-57. PubMed ID: 12177115
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab-induced tumor progression: does it really happen?
    Ozguroglu M; Turna H
    Med Oncol; 2004; 21(2):205-6. PubMed ID: 15299193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NICE announces guidelines for use of rituximab.
    Mayor S
    BMJ; 2003 Oct; 327(7418):766. PubMed ID: 14525854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.